DDO-6600

Overview

DDO-6600 is a covalent Hsp90 inhibitor. DDO-6600 disrupts the interaction between Hsp90 and its co-chaperone protein Cdc37, thereby inducing the degradation of kinase client proteins (such as AKT , CDK4 , c-Raf ). DDO-6600 has inhibitory activity against various cancer cells. DDO-6600 inhibits the migration and invasion of HCT-116 cells, and induces cell cycle arrest and apoptosis . DDO-6600 significantly inhibits tumor growth in the HCT-116 xenograft tumor model. DDO-6600 can be used for research on colorectal cancer .

Application

Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Raf | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > HSP | Products > Signaling Pathways > Akt | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-147125
• CAS No.: 2640292-37-9
• Molecular Formula: C26H28N4O2
• Molecular Weight: 428.53
• Purity: 98.19%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source